Sign In
Buy PBM
$3.17
-0.190 (-5.65%)
At Close: Jul 31, 2026
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
06:30pm, Friday, 13'th Feb 2026
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby secu
Psyence BioMed Announces Settlement of Shareholder Litigation
09:15am, Wednesday, 11'th Feb 2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direc
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
06:30pm, Wednesday, 28'th Jan 2026
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
01:42pm, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareh
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
07:19am, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced
Psyence Biomedical Shares Set to Reverse Split on Tuesday, January 20th (NASDAQ:PBM)
01:18am, Friday, 16'th Jan 2026
Psyence Biomedical Ltd. (NASDAQ: PBM) shares are set to reverse split on the morning of Tuesday, January 20th. The 1-6.25 reverse split was recently announced. The number of shares owned by shareholde
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
07:00pm, Wednesday, 14'th Jan 2026
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
08:30am, Monday, 12'th Jan 2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
09:15am, Monday, 05'th Jan 2026
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Update
02:35am, Sunday, 28'th Dec 2025
Psyence Biomedical Ltd. (NASDAQ: PBM - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totaling 312,062 shares, a g
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
09:48am, Friday, 19'th Dec 2025
DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driv
Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial
07:00am, Friday, 19'th Dec 2025
With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trials With approxima
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Psyence Biomedical (NASDAQ:PBM) Trading Down 2.5% – Should You Sell?
02:38am, Wednesday, 03'rd Dec 2025
Shares of Psyence Biomedical Ltd. (NASDAQ: PBM - Get Free Report) dropped 2.5% during mid-day trading on Tuesday. The stock traded as low as $1.51 and last traded at $1.58. Approximately 115,404 share
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
07:00am, Tuesday, 25'th Nov 2025
First publicly listed company to actively investigate psilocybin's potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”
